Last edition
News about
Lishan Biotech secures exclusive worldwide rights to develop and commercialise BMC128, a Phase I microbiome-based immunotherapy candidate showing early promise in lung and renal cancers.
Slingshot Backs New Precision Oncology Venture from Crick Research
Slingshot Therapeutics, Syncona’s accelerator platform for advancing early-stage drug discovery programmes, has launched ALTx Therapeutics with an initial £12.55 million funding commitment from Syncona, the Francis Crick Institute, and Cancer Research Horizons.
Pfizer Launches Cost Savings Programme on TrumpRx
Pfizer has rolled out a new cost-savings initiative, TrumpRx, aimed at making medicines more affordable for US patients. The programme covers over 30 brands across major therapy areas and reinforces the company’s commitment to lowering drug prices under its landmark agreement with the Trump administration.
Akeso Secures Fifth NMPA Breakthrough Designation for Ivonescimab
The breakthrough designation supports ivonescimab combined with chemotherapy for first-line treatment of advanced Biliary Tract Cancer (BTC), based on an ongoing phase-III study comparing it with durvalumab-based chemotherapy.
PharmaResearch Wins FDA Clearance for Phase-I Trial of PRD-101
PRD-101 is a next-generation nano anti-cancer drug candidate formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT (DNA Optimising Technology).
GSK Wins European Nod for Nucala to Treat Eosinophilic COPD
GSK plc has received European Commission approval for Nucala (mepolizumab) as an add-on maintenance therapy for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by elevated blood eosinophils, despite treatment with inhaled triple therapy.
New Invivoscribe Platform Targets KMT2A Rearrangements in AML Trials
Invivoscribe, a precision diagnostics company focused on measurable residual disease (MRD) testing, has expanded its oncology portfolio with the launch of the LeukoStrat KMT2A + MRD Assay and Software.
FDA Warns It Will Take Action on Misleading Copycat Drug Marketing
The United States Food and Drug Administration (FDA) has warned it will take swift action against companies that mass-market unapproved “copycat” drugs by promoting them as if they were similar to FDA-approved products, the agency’s commissioner said.
Zydus Gets USFDA Tentative Nod for Dapagliflozin Tablets
Zydus has received tentative approval from the US Food and Drug Administration (USFDA) for dapagliflozin tablets in 5 mg and 10 mg strengths, paving the way for the company’s entry into the US market subject to final approval.
Angitia Biopharmaceuticals Bags USD 130 Million in Series D Capital Raise
Angitia Biopharmaceuticals has raised USD 130 million in a Series D financing round co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners. The funds will be used to advance the clinical development of lead programmes AGA2118, AGA2115, AGA111 and other pipeline assets.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy